Compare AKBA & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | MRBK |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 235.5M |
| IPO Year | 2014 | 2018 |
| Metric | AKBA | MRBK |
|---|---|---|
| Price | $1.22 | $19.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.67 | ★ $20.75 |
| AVG Volume (30 Days) | ★ 4.1M | 140.5K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.05% |
| EPS Growth | ★ 93.94 | 30.34 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $6,316,000.00 |
| Revenue This Year | N/A | $25.40 |
| Revenue Next Year | N/A | $8.15 |
| P/E Ratio | ★ N/A | $116.41 |
| Revenue Growth | N/A | ★ 10.13 |
| 52 Week Low | $0.82 | $13.81 |
| 52 Week High | $3.81 | $21.59 |
| Indicator | AKBA | MRBK |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 51.87 |
| Support Level | $1.16 | $18.42 |
| Resistance Level | $1.52 | $20.72 |
| Average True Range (ATR) | 0.07 | 0.55 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 7.59 | 43.62 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.